Optimizing the use of ATRA in conjunction with other FR-inducing treatments, represented by HDAC, may not only extend the therapeutic reach of ATRA in AML, but also the efficacy of FRβ-targeted therapy. Here, HDAC9 is linked to acute myeloid leukemia.